C

    Conduit Pharmaceuticals Inc. (CDT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.68
    -0.01 (-0.59%)

    Market Cap: $1.33M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    PeriodReportedEst.SurpriseB/MYoY
    Jun 26
    		$-8.71N/AN/ABeat-59.4%
    Mar 26
    		$-99.99N/AN/ABeat-7475.0%
    Dec 25
    		$-2314.41N/AN/ABeat-107547.1%
    Sep 25
    		$-13.16N/AN/ABeat+100.0%
    Jun 25
    		$-5.46N/AN/ABeat+100.0%
    Mar 25
    		$-1.32N/AN/ABeat+100.0%
    Dec 24
    		$-2.15N/AN/ABeat+100.0%
    Sep 24
    		$-222396.70N/AN/ABeat-2315.1%
    Jun 24
    		$-218668.69N/AN/ABeat-32.5%
    Mar 24
    		$-145104.50N/AN/ABeat-248.6%
    Dec 23
    		$-45824.50N/AN/ABeat-152748418.7%
    Sep 23
    		$-9208.77N/AN/ABeat-92087815.0%
    Jun 23
    		$-165034.67N/AN/ABeat-1650346622.0%
    Mar 23
    		$97628.07N/AN/ABeat+488140467.5%
    Dec 22
    		$0.03$0.00N/ABeat-
    Sep 22
    		$0.01$0.00N/ABeat-
    Jun 22
    		$-0.01$0.00N/AMiss-
    Mar 22
    		$-0.02$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-0.00EV/EBITDA-55.41x
    Price/FCF-51.07xFCF Yield-1.96%
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-69.70%ROIC4.21%
    Financial Health
    Debt/Equity0.95xInterest Coverage3.24x
    Current Ratio2.14xQuick Ratio1.49x
    Trading Statistics
    Beta1.49Avg Volume116.17K
    52-Week High$272.0052-Week Low$0.30

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$2.33
    SMA 20$2.73
    SMA 50$3.99
    SMA 200$153.89
    EMA 10$2.20
    EMA 20$2.62
    EMA 50$7.81
    EMA 200$1443.59

    MACD

    Line: -0.66Signal: -0.67Hist: 0.00

    ADX

    ADX: 30.6+DI: 7.1-DI: 10.0

    Aroon & PSAR

    Aroon Up28.0
    Aroon Down100.0
    PSAR$3.33

    Bollinger Bands

    Upper Band$3.89
    Lower Band$1.57
    %B Position8484%(Upper)
    Band Width0.05

    RSI (14-Day)

    Oversold
    28.0

    Momentum Oscillators

    Stoch %K4.4
    Stoch %D4.7
    Williams %R-95.6
    ROC (10d)-40.1%
    Momentum-1.12
    CCI (20d)-158.5
    MFI (14d)12.0

    Volatility Measures

    ATR (14d)$0.99(59.2%)
    StdDev (20d)0.58
    Hist Vol128.0%(High)

    Volume Flow

    VWAP$1.69
    OBV469.1M
    AD Line55827.8B
    CMF (20d)-0.332

    Volume Metrics

    Avg Vol (20d)119.4K
    Vol Ratio1.1x
    VWMA (20d)$2.43

    Pivot Points

    R3$2.35
    R2$2.19
    R1$1.94
    Pivot Point$1.78
    S1$1.53
    S2$1.37
    S3$1.12

    Advanced Oscillators

    TSI-33.22
    Ultimate Osc23.5
    KST-299.01

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$750.16M$696.38M$2.72B$698.22M$671.99M$624.86M$1.08B$654.93M$-1,345,343,000$535.67M$0$0
    Cost of Revenue$449.13M$438.29M$515,000$885,000$828,000$190,000$452,000$5,000$377.53M$334.08MN/AN/A
    Gross Profit$301.03M$258.09M$-515,000$-885,000$-828,000$-190,000$-452,000$-5,000$-695,873,000$201.60MN/AN/A
    Operating Expenses$183.66M$180.13M$21.16M$7.03M$4.95M$3.62M$3.51M$5.81M$3.14M$2.96M$895,000$430,000
    R&D$32.91M$30.09M$746,000$1.53M$1.86M$916,000$132,000$3.09M$25,000$128,000$90,000$0
    SG&A$0$138.65M$20.41M$5.50M$3.09M$2.70M$3.38M$2.72M$3.12M$2.83M$805,000$430,000
    Operating Income$117.37M$77.96M$-21,156,000$-7,033,000$-4,952,000$-3,616,000$-3,513,000$-5,811,000$-3,140,000$-2,955,000$-895,000$-430,000
    Interest Income$0$0$9,000$7,000$4,000$8,000$2,000$8,000$2,000$9,000$0$0
    Interest Expense$40.52M$13.46M$38,000$48,000$57,000$176,000$960,000$310,000$119,000$119,000$330,000$47,000
    Income Before Tax$85.20M$62.77M$-21,325,000$-7,118,000$-6,028,000$-4,753,000$-2,406,000$-6,461,000$-5,383,000$-3,552,000$1.78M$2.63M
    Income Tax Expense$16.67M$11.74M$29.44M$-97,000$-5,666,000$-10,144,000$10,000$-60,153,000$-11,091,000$-8,360,000$300,000$47,000
    Net Income$68.54M$51.03M$-21,325,000$-7,118,000$-6,028,000$-4,753,000$-2,406,000$-6,461,000$-5,383,000$-3,552,000$1.78M$2.63M
    EBITDA$159.66M$108.69M$-18,878,000$-6,185,000$-5,143,000$-4,380,000$-994,000$-6,146,000$18.25M$-3,433,000$1.90M$2.63M
    EBIT$127.20M$76.23M$-21,287,000$-7,070,000$-5,971,000$-4,577,000$-1,446,000$-6,151,000$-5,264,000$-29,942,000$1.86M$2.03M
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about CDT

    News

    Pep?d Inc. announced that it has received funding from CDT Equity Inc.

    Pep?d Inc. has secured a round of funding on August 25, 2026, with new investor CDT Equity Inc. participating. The funding was provided through a simple agreement for future equity. This announcement highlights CDT Equity Inc.'s continued activity in the investment landscape.

    www.marketscreener.com•8/25/26•
    Somewhat-Bullish

    The global peptide therapeutics market is projected to reach $294.6B by 2033; CDT invests in Pep'd

    CDT Equity Inc. (Nasdaq: CDT) has invested in US-based peptide company Pep'd via a SAFE note with a $10 million valuation cap, gaining exposure to the rapidly expanding US peptide market. This move aligns with CDT's strategy to back science-driven, AI-enabled platforms in therapeutics, despite a related-party transaction where Pep'd is controlled by CDT's CEO. The global peptide therapeutics market is projected to grow from $164.0 billion in 2026 to $294.6 billion by 2033, indicating significant sector growth.

    Stock Titan•8/25/26•
    Bearish

    Price to book forward of CDT Equity Inc. – NASDAQ:CDTTW

    This article provides financial information for CDT Equity Inc. under the NASDAQ:CDTTW ticker. It focuses on the "Price to book forward" metric for the company. The content appears to be a financial data page from TradingView.

    TradingView•8/24/26•
    Neutral

    Price to earnings forward of CDT Equity Inc. – NASDAQ:CDTTW

    This article provides financial data for CDT Equity Inc. (NASDAQ:CDTTW), specifically focusing on its forward price-to-earnings ratio. The content is presented as a snapshot from a financial data platform, indicating the company's stock market information and relevant financial metrics.

    TradingView•8/23/26•
    Neutral

    New 5.3% passive stake surfaces in CDT Equity Inc. (CDT)

    A Schedule 13G filing reveals that a group of related investment entities, including Primary Development Fund (Cayman) SPC, E2 Trust, E3 Fund SP, and IALC Trustees SA, have collectively acquired a 5.3% passive stake in CDT Equity Inc. (CDT). This ownership amounts to 41,673 shares of common stock, based on 786,670 shares outstanding as of August 12, 2026, and accounts for the company's recent 1-for-25 and 1-for-10 reverse stock splits. The entities share both voting and dispositive power over these shares, with the investment noted as passive and not intended to influence control.

    Stock Titan•8/21/26•
    Neutral

    Frequently Asked Questions About CDT

    Does CDT pay dividends?
    Conduit Pharmaceuticals Inc. (CDT) does not currently pay a regular dividend.
    What is CDT's market cap?
    Conduit Pharmaceuticals Inc. (CDT) has a market capitalization of $1.33M with a current stock price of $1.68.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In